A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers.
COVID-19 vaccination
booster third dose
immunogenicity
solid cancer
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
23 May 2023
23 May 2023
Historique:
received:
01
04
2023
revised:
17
05
2023
accepted:
22
05
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Patients with solid malignancies on active treatment were followed up after the primary course and booster third dose of vaccination to assess their anti-SARS-CoV-2 S1 IgG levels, efficacy in the case of SARS-CoV-2 infection, and safety. Out of 125 patients receiving the primary course of vaccination, 66 patients received a booster third dose of mRNA vaccine, with a 20-fold increase in median anti-SARS-CoV-2 S1 IgG levels compared to Ab levels six months post-primary course of vaccination ( The third booster vaccination dose against COVID-19 in solid cancer patients triggers substantial immunogenicity and is safe and effective for preventing a severe COVID-19 disease course.
Sections du résumé
BACKGROUND
BACKGROUND
The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort.
METHODS
METHODS
Patients with solid malignancies on active treatment were followed up after the primary course and booster third dose of vaccination to assess their anti-SARS-CoV-2 S1 IgG levels, efficacy in the case of SARS-CoV-2 infection, and safety.
RESULTS
RESULTS
Out of 125 patients receiving the primary course of vaccination, 66 patients received a booster third dose of mRNA vaccine, with a 20-fold increase in median anti-SARS-CoV-2 S1 IgG levels compared to Ab levels six months post-primary course of vaccination (
CONCLUSION
CONCLUSIONS
The third booster vaccination dose against COVID-19 in solid cancer patients triggers substantial immunogenicity and is safe and effective for preventing a severe COVID-19 disease course.
Identifiants
pubmed: 37376406
pii: vaccines11061017
doi: 10.3390/vaccines11061017
pmc: PMC10301109
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Slovenian Research Agency
ID : P3-0360
Références
Future Oncol. 2022 Jul;18(23):2537-2550
pubmed: 35678621
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
Lancet Oncol. 2021 Dec;22(12):1681-1691
pubmed: 34767759
Ann Oncol. 2021 Aug;32(8):1053-1055
pubmed: 33932508
Nat Cancer. 2021 Dec;2(12):1305-1320
pubmed: 35121899
Eur J Cancer. 2022 Mar;163:177-179
pubmed: 35077960
JAMA Oncol. 2022 Apr 01;8(4):612-617
pubmed: 34994776
J Clin Oncol. 2022 Jan 1;40(1):12-23
pubmed: 34752147
ESMO Open. 2022 Apr;7(2):100458
pubmed: 35427842
Cancers (Basel). 2021 Sep 23;13(19):
pubmed: 34638235
Ann Oncol. 2022 May;33(5):563-565
pubmed: 35202794
ESMO Open. 2021 Oct;6(5):100274
pubmed: 34597941
Vaccine. 2022 Mar 1;40(10):1483-1492
pubmed: 35131133
Nat Cancer. 2021 Apr;2(4):392-399
pubmed: 34661163
Ann Oncol. 2022 Feb;33(2):158-168
pubmed: 34718117
Cancers (Basel). 2021 Sep 06;13(17):
pubmed: 34503290
ESMO Open. 2022 Jun;7(3):100499
pubmed: 35644101
Vaccines (Basel). 2023 Mar 31;11(4):
pubmed: 37112691
Ann Oncol. 2021 Oct;32(10):1294-1295
pubmed: 34171494
Eur J Cancer. 2022 Feb;162:182-193
pubmed: 35016032
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
Nat Med. 2021 Nov;27(11):2002-2011
pubmed: 34594036
Vaccines (Basel). 2022 Apr 04;10(4):
pubmed: 35455306
ESMO Open. 2022 Oct;7(5):100574
pubmed: 36029652
Microorganisms. 2021 Mar 31;9(4):
pubmed: 33807490
JAMA Oncol. 2022 Feb 1;8(2):300-301
pubmed: 34812840
Cancer Cell. 2022 Feb 14;40(2):114-116
pubmed: 34968417
Cancer Cell. 2022 Jan 10;40(1):3-5
pubmed: 34838186
Cancer Cell. 2022 Jan 10;40(1):103-108.e2
pubmed: 34990570
Eur J Cancer. 2022 Nov;176:164-167
pubmed: 36223679
Vaccines (Basel). 2022 Apr 15;10(4):
pubmed: 35455367
Cancer Res Treat. 2023 Feb 09;:
pubmed: 36758955
Cancer Cell. 2022 Feb 14;40(2):117-119
pubmed: 34986328
Br J Cancer. 2022 Nov;127(10):1827-1836
pubmed: 36224402